KR101334456B1 - Ｃ-ｍｅｔ의 억제제로서 유용한 아미도페녹시인다졸 - Google Patents

Ｃ-ｍｅｔ의 억제제로서 유용한 아미도페녹시인다졸 Download PDF

Info

Publication number
KR101334456B1
KR101334456B1 KR1020117001628A KR20117001628A KR101334456B1 KR 101334456 B1 KR101334456 B1 KR 101334456B1 KR 1020117001628 A KR1020117001628 A KR 1020117001628A KR 20117001628 A KR20117001628 A KR 20117001628A KR 101334456 B1 KR101334456 B1 KR 101334456B1
Authority
KR
South Korea
Prior art keywords
mmol
methyl
added
fluoro
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117001628A
Other languages
English (en)
Korean (ko)
Other versions
KR20110022691A (ko
Inventor
티차오 리
마크 앤드류 포반즈
추안 시
지페이 우
웨이 제니퍼 양
보유 종
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20110022691A publication Critical patent/KR20110022691A/ko
Application granted granted Critical
Publication of KR101334456B1 publication Critical patent/KR101334456B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117001628A 2008-07-24 2009-07-15 Ｃ-ｍｅｔ의 억제제로서 유용한 아미도페녹시인다졸 Expired - Fee Related KR101334456B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US61/083,294 2008-07-24
US8508208P 2008-07-31 2008-07-31
US61/085,082 2008-07-31
US10865908P 2008-10-27 2008-10-27
US61/108,659 2008-10-27
PCT/US2009/050640 WO2010011538A1 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met

Publications (2)

Publication Number Publication Date
KR20110022691A KR20110022691A (ko) 2011-03-07
KR101334456B1 true KR101334456B1 (ko) 2013-11-29

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117001628A Expired - Fee Related KR101334456B1 (ko) 2008-07-24 2009-07-15 Ｃ-ｍｅｔ의 억제제로서 유용한 아미도페녹시인다졸

Country Status (35)

Country Link
US (2) US8030302B2 (https=)
EP (1) EP2310382B1 (https=)
JP (1) JP5414794B2 (https=)
KR (1) KR101334456B1 (https=)
CN (1) CN102105462B (https=)
AR (1) AR074632A1 (https=)
AT (1) ATE546444T1 (https=)
AU (1) AU2009274256B2 (https=)
BR (1) BRPI0916286B8 (https=)
CA (1) CA2731773C (https=)
CL (1) CL2011000134A1 (https=)
CO (1) CO6351737A2 (https=)
CR (1) CR20110046A (https=)
CY (1) CY1112595T1 (https=)
DK (1) DK2310382T3 (https=)
DO (1) DOP2011000009A (https=)
EA (1) EA018385B1 (https=)
EC (1) ECSP11010778A (https=)
ES (1) ES2379587T3 (https=)
HR (1) HRP20120202T1 (https=)
IL (1) IL210490A (https=)
JO (1) JO2788B1 (https=)
MA (1) MA32594B1 (https=)
MX (1) MX2011000925A (https=)
MY (1) MY163852A (https=)
NZ (1) NZ590013A (https=)
PE (1) PE20110150A1 (https=)
PL (1) PL2310382T3 (https=)
PT (1) PT2310382E (https=)
RS (1) RS52261B (https=)
SI (1) SI2310382T1 (https=)
SV (1) SV2011003816A (https=)
TW (1) TWI365185B (https=)
WO (1) WO2010011538A1 (https=)
ZA (1) ZA201100219B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2599458T3 (es) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
US8962623B2 (en) * 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
WO2013169532A1 (en) * 2012-05-09 2013-11-14 Eli Lilly And Company Anti-c-met antibodies
WO2014134313A1 (en) * 2013-02-27 2014-09-04 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
US20190336599A1 (en) * 2016-04-15 2019-11-07 Eli Lilly And Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
WO2018022438A1 (en) * 2016-07-29 2018-02-01 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
JP6709340B2 (ja) 2016-11-16 2020-06-10 イーライ リリー アンド カンパニー エクソン１４スキッピング変異（複数可）またはエクソン１４スキッピング表現型を有するがんの併用療法
WO2018093654A1 (en) 2016-11-16 2018-05-24 Eli Lilly And Company Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
US11623923B2 (en) 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
WO2019182274A1 (en) 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
JP7443373B2 (ja) * 2018-09-03 2024-03-05 タイリガンド バイオサイエンス（シャンハイ）リミテッド 抗がん性薬物としてのｔｒｋ阻害剤
EP3819300A4 (en) 2019-09-06 2021-11-24 Wellmarker Bio Co., Ltd. THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
KR20220170766A (ko) * 2021-06-22 2022-12-30 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004006A1 (en) 2004-06-28 2006-01-05 Borzilleri Robert M Pyrrolotriazine kinase inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
ES2268015T3 (es) * 2001-05-18 2007-03-16 Srl, Inc. Procedimiento de inmunoensayo.
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US6986913B2 (en) * 2003-07-17 2006-01-17 Dynal Biotech Asa Process
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
EP2038320B1 (en) * 2006-06-29 2014-03-12 Life Technologies AS Particles containing multi- block polymers
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
KR101550250B1 (ko) 2007-06-27 2015-09-04 알케마 인코포레이티드 하이드로플루오로올레핀의 제조 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004006A1 (en) 2004-06-28 2006-01-05 Borzilleri Robert M Pyrrolotriazine kinase inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use

Also Published As

Publication number Publication date
IL210490A0 (en) 2011-03-31
AR074632A1 (es) 2011-02-02
IL210490A (en) 2013-06-27
MX2011000925A (es) 2011-03-21
CR20110046A (es) 2011-04-27
HK1155172A1 (en) 2012-05-11
US20100022529A1 (en) 2010-01-28
HRP20120202T1 (hr) 2012-03-31
CA2731773C (en) 2013-03-12
MA32594B1 (fr) 2011-09-01
PE20110150A1 (es) 2011-03-07
TWI365185B (en) 2012-06-01
ECSP11010778A (es) 2011-02-28
SV2011003816A (es) 2011-03-17
EA201170252A1 (ru) 2011-06-30
DOP2011000009A (es) 2011-03-31
ES2379587T3 (es) 2012-04-27
JP2011529054A (ja) 2011-12-01
MY163852A (en) 2017-10-31
KR20110022691A (ko) 2011-03-07
CA2731773A1 (en) 2010-01-28
PT2310382E (pt) 2012-04-11
JO2788B1 (en) 2014-03-15
PL2310382T3 (pl) 2012-07-31
JP5414794B2 (ja) 2014-02-12
BRPI0916286B8 (pt) 2021-05-25
CO6351737A2 (es) 2011-12-20
AU2009274256A1 (en) 2010-01-28
ATE546444T1 (de) 2012-03-15
USRE43878E1 (en) 2012-12-25
DK2310382T3 (da) 2012-03-26
CN102105462A (zh) 2011-06-22
RS52261B (sr) 2012-10-31
BRPI0916286B1 (pt) 2019-10-08
EP2310382A1 (en) 2011-04-20
EP2310382B1 (en) 2012-02-22
CN102105462B (zh) 2014-07-23
CY1112595T1 (el) 2016-02-10
US8030302B2 (en) 2011-10-04
CL2011000134A1 (es) 2011-07-08
EA018385B1 (ru) 2013-07-30
NZ590013A (en) 2012-06-29
WO2010011538A1 (en) 2010-01-28
SI2310382T1 (sl) 2012-04-30
TW201006817A (en) 2010-02-16
AU2009274256B2 (en) 2013-07-11
ZA201100219B (en) 2012-06-27

Similar Documents

Publication Publication Date Title
KR101334456B1 (ko) Ｃ-ｍｅｔ의 억제제로서 유용한 아미도페녹시인다졸
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
CN103874690B (zh) 含酰肼的核运输调节剂及其用途
JP6377081B2 (ja) 新規ピリミジン化合物
US8436011B2 (en) Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
CN107793413A (zh) 嘧啶杂环化合物及其制备方法和应用
WO2018228275A1 (zh) 作为mnk抑制剂的杂环化合物
CN103732067A (zh) 化合物，组合物及它们的治疗用途
US9353107B2 (en) 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
TW201302730A (zh) 吡唑化合物
US20150166505A1 (en) Pyridinyl-substituted pyrazolyl carboxamides
CN115785154A (zh) 杂芳环化合物及其医药用途
CN114555597A (zh) 异柠檬酸脱氢酶（idh）抑制剂
KR102333854B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
HK1155172B (en) Amidophenoxyindazoles useful as inhibitors of c-met
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
HK1210774B (en) Substituted 2-aminopyridine protein kinase inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211123

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211123